non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatosis hepatitis (NASH)
Conditions
Interventions
Gold Standard:MRI-PDFF uses the chemical shift-encoded (CSE) MRI methods that can quantify the relative amount of water and fat signal arising from tissue. CSE methods can accurately quantify the PDFF
Index test:The 
endpoints 
of 
the 
quantitative 
ultrasound 
biomarkers 
to 
be 
correlated 
with 
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old, able to provide written informed consent; 2. Eligible for standard abdominal ultrasound examination and standard non-enhanced MRI examination; 3. Attest to absent or minimal alcohol consumption (less than 30g of ethyl alcohol /day for men and less than 20g of ethyl alcohol /day for women); 4. At least meet one of the following criteria: (1) Overweight or obese (BMI >= 25); (2) Diagnosed with T2DM according to clinical guidelines; (3) Diagnosed with hypercholesterolemia according to clinical guidelines; (4) Diagnosed with or clinically suspected of NAFLD / NASH based on previous medical history, imaging examination, liver biopsy and/or other laboratory tests.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Subjects with evidence of hepatotoxicity; 3. Subjects with a history of chronic liver disease (e.g. viral hepatitis, cholestatic hepatitis, or autoimmune liver disease); 4. Subjects taking medication associated with liver steatosis, including amiodarone, methotrexate, nucleoside reverse transcriptase inhibitors (didanosine, deoxythymidine), valproate, dexamethasone, tamoxifen, adjuvant chemotherapy based on 5-fluorouracil, apolipoprotein B inhibitors; 5. During the enrollment period, subjects anticipated or planned diagnostic or therapeutic intervention and the Investigator believes this may affect the liver fat content (e.g., bariatric surgery, chemotherapy); 6. Subjects with unstable clinical status, late stages of a given disease, or unpredictable clinical 7. Subjects with evidence of COVID-19 or with the substantial risk of COVID-19 infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepato-renal index (HRI);Acoustic attenuation;Tissue stiffness; | — |
Countries
China
Contacts
Public ContactLu Qiang
West China Hospital of Sichuan University
Outcome results
None listed